Other
Oral Submucous Fibrosis
12
Pipeline Programs↗
2
Active Trials↗
6
Companies Involved↗
Oral Submucous Fibrosis is an emerging landscape with 12 programs across 6 companies. The most active players are Boehringer Ingelheim, Validus Pharmaceuticals, Primus Pharmaceuticals. 1 therapy is approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 36
Approved1
Analysis
Trial Status
8
clinical trials
Completed4 · 50%
Unknown status2 · 25%
Not yet recruiting2 · 25%
Clinical Trials
Trial Activity
8 trials
Comparison of Curcumin and Intralesional Steroids in Oral Submucous Fibrosis
Not yet recruiting·SServices Institute of Medical Sciences, Pakistan·Phase 3·NCT06758739·70 enrolled
Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis
Not yet recruiting·—·N/A·NCT07277998·40 enrolled
Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis
Completed·—·Phase 4·NCT05660694·40 enrolled
Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study
Completed·TThe Oxford Dental College, Hospital and Research Center, Bangalore, India·Phase 3·NCT02714543·74 enrolled
Efficacy of Curcumin in Oral Submucous Fibrosis
Unknown status·HH.K.E.S's S.Nijalingappa Institute of Dental Science and Research·Phase 2·NCT03511261·200 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)